Healthcare / Medical DistributionParis
$25.30
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $41.7M · quality 41.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$185M
P/E
20.1x
↓EV/EBITDA
5.7x
↓ROE
0.7%
↑Gross Margin
67.8%
↑Debt/Equity
5.70
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.6%
FCF CAGR
+126.6%
FCF margin
8.5%
FCF / Net income
79.06x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $491.2M · net income $528000.0 · FCF $41.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $491.2M | $491.2M | $461.9M | $508.0M | $468.3M |
| Net Income | $528000.00 | $528000.00 | $-900000.00 | $12.0M | $13.7M |
| EBITDA | $102.0M | $102.0M | $95.2M | $98.2M | $90.6M |
| EPS | 0.07 | 0.07 | -0.12 | 1.52 | 1.86 |
| Gross Margin | 67.8% | 67.8% | 66.8% | 65.7% | 65.5% |
| Operating Margin | 9.2% | 9.2% | 8.3% | 8.4% | 8.3% |
| Net Margin | 0.1% | 0.1% | -0.2% | 2.4% | 2.9% |
| Balance Sheet | |||||
| Debt/Equity | 5.70 | 5.70 | 5.12 | 4.88 | 4.96 |
| Current Ratio | 1.16 | 1.16 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $41.7M | $41.7M | $24.5M | $52.0M | $3.6M |
| Returns | |||||
| ROE | 0.7% | 0.7% | -1.1% | 13.7% | 16.2% |
| Valuation | |||||
| P/E | 20.08 | 20.08 | — | 19.14 | 17.93 |
| EV/EBITDA | 5.75 | 5.75 | 5.72 | 6.33 | 7.09 |
| P/B | 2.78 | 2.78 | 2.00 | 2.64 | 2.91 |
| Growth & Yield | |||||
| Revenue Growth | 6.3% | 6.3% | -9.1% | 8.5% | — |
| EPS Growth | 158.3% | 158.3% | -107.9% | -18.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
217.7%
EPS terminal req.
$2.24
Spread vs growth
-59.4%
5Y implied EPS CAGR
107.9%
EPS terminal req.
$2.72
Spread vs growth
50.5%
10Y implied EPS CAGR
51.2%
EPS terminal req.
$4.37
Spread vs growth
107.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-7.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.12 → 0.07
Residual
-7.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.